Intercept sues Apotex over Ocaliva generic

26-08-2020

Rory O'Neill

Intercept sues Apotex over Ocaliva generic

JHVEPhoto / Shutterstock.com

Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva (obeticholic acid).


Intercept, Apotex, Ocaliva, Delaware, ANDA, generic, obeticholic acid, UDCA, ursodeoxycholic acid, primary biliary cholangitis, autoimmune

LSIPR